Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide in MCI and Mild Alzheimer's Disease (NEAT)
NCT03061474Phase 2Completed
- Sponsor
- University of California, Irvine
- Start
- Jul 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by University of California, Irvine. Started Jul 2017; status: completed.
02
Drugs
nicotinamide
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03061474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061474.